{"product_id":"lung-cancer-9781118468746","title":"Lung Cancer","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eLung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. This book provides the research in the identification of biomarkers to predict a high risk for developing lung cancer.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.”  (\u003ci\u003eKingbook73's Medical Ebook and Video Collection\u003c\/i\u003e, 19 September 2014)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eContributors, viii\u003c\/p\u003e \u003cp\u003ePreface, xiii\u003c\/p\u003e \u003cp\u003e1 Smoking Prevention and Cessation, 1\u003cbr\u003e\u003ci\u003eAlexander V. Prokhorov and Karen Suchanek Hudmon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Lung Cancer Susceptibility and Risk Assessment Models, 25\u003cbr\u003e\u003ci\u003eXifeng Wu, Xia Pu, and Jie Lin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Molecular Profiling, 48\u003cbr\u003e\u003ci\u003eLauren Averett Byers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Somatic Genome Alterations in Human Lung Cancers, 67\u003cbr\u003e\u003ci\u003eMarcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Serum Proteomic Biomarkers, 90\u003cbr\u003e\u003ci\u003eMohamed Hassanein and David P. Carbone\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Molecular Biology of Lung Preneoplasia, 110\u003cbr\u003e\u003ci\u003eHumam Kadara and Ignacio I. Wistuba\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Detection and Treatment of Preneoplastic Lesions, 129\u003cbr\u003e\u003ci\u003eRachel Jen and Stephen Lam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Pathology of Adenocarcinoma, 144\u003cbr\u003e\u003ci\u003eWilliam D. Travis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158\u003cbr\u003e\u003ci\u003eHoward West\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Radiology and Lung Cancer Screening, 176\u003cbr\u003e\u003ci\u003ePatricia de Groot and Reginald F. Munden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Imaging Lung Cancer, 191\u003cbr\u003e\u003ci\u003eSonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Staging of the Mediastinum, 202\u003cbr\u003e\u003ci\u003eMauricio Pipkin and Shaf Keshavjee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Management of the Solitary Pulmonary Nodule, 214\u003cbr\u003e\u003ci\u003eMin P. Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Minimally Invasive Resections for Lung Cancer, 224\u003cbr\u003e\u003ci\u003eShanda H. Blackmon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Extended Resections for Lung Cancer, 236\u003cbr\u003e\u003ci\u003eMatthew A. Steliga and David C. Rice\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Bronchoscopic Interventions for Lung Cancer, 253\u003cbr\u003e\u003ci\u003eDonald R. Lazarus and George A. Eapen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Primary Tracheal Tumors, 267\u003cbr\u003e\u003ci\u003eFrancesco Sammartino and Paolo Macchiarini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278\u003cbr\u003e\u003ci\u003eKathryn A. Gold\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290\u003cbr\u003e\u003ci\u003eChristopher G. Azzoli and Katherine M.W. Pisters\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Image-Guided Radiation Therapy, 309\u003cbr\u003e\u003ci\u003eKenneth E. Rosenzweig and Sonal Sura\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320\u003cbr\u003e\u003ci\u003ePuneeth Iyengar and Robert D. Timmerman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Proton Therapy, 338\u003cbr\u003e\u003ci\u003eJoe Y. Chang and James D. Cox\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353\u003cbr\u003e\u003ci\u003eDaniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379\u003cbr\u003e\u003ci\u003eHeath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390\u003cbr\u003e\u003ci\u003eSteven H. Lin and Ritsuko U. Komaki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406\u003cbr\u003e\u003ci\u003eKathryn F. Mileham, Edward S. Kim, and William N. William Jr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421\u003cbr\u003e\u003ci\u003eErminia Massarelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435\u003cbr\u003e\u003ci\u003eLucia Kim, Geoffrey Liu, and Ming-Sound Tsao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Immunologic Approaches to Lung Cancer Therapy, 454\u003cbr\u003e\u003ci\u003eJay M. Lee, Steven M. Dubinett, and Sherven Sharma\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Novel and Emerging Agents in NSCLC, 464\u003cbr\u003e\u003ci\u003eAnne S. Tsao and Jack A. Roth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479\u003cbr\u003e\u003ci\u003eVassiliki A. Papadimitrakopoulou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Novel Statistical Models for NSCLC Clinical Trials, 488\u003cbr\u003e\u003ci\u003eJ. Jack Lee and Caleb T. Chu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505\u003cbr\u003e\u003ci\u003eJohn V. Heymach and Tina Cascone\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Anti-angiogenic Agents in Metastatic NSCLC, 527\u003cbr\u003e\u003ci\u003eMillie Das and Heather Wakelee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Targeting ALK Rearrangements, 541\u003cbr\u003e\u003ci\u003eJustin F. Gainor and Alice T. Shaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557\u003cbr\u003e\u003ci\u003eRenata Ferrarotto and George R. Simon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Prognostic and Predictive Biomarker Signatures, 564\u003cbr\u003e\u003ci\u003eJohannes R. Kratz and David M. Jablons\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Brain Metastasis from Lung Cancer, 572\u003cbr\u003e\u003ci\u003eRitsuko U. Komaki and Amol J. Ghia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 591\u003c\/p\u003e \u003cp\u003eColor plate section between pages 146 and 147\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49406875468119,"sku":"9781118468746","price":145.76,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781118468746.jpg?v=1730497412","url":"https:\/\/bookcurl.com\/products\/lung-cancer-9781118468746","provider":"Book Curl","version":"1.0","type":"link"}